KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Equity Average (2019 - 2025)

Royalty Pharma's Equity Average history spans 7 years, with the latest figure at $9.7 billion for Q4 2025.

  • For Q4 2025, Equity Average fell 6.14% year-over-year to $9.7 billion; the TTM value through Dec 2025 reached $9.7 billion, down 6.14%, while the annual FY2025 figure was $10.0 billion, 1.81% down from the prior year.
  • Equity Average for Q4 2025 was $9.7 billion at Royalty Pharma, up from $9.6 billion in the prior quarter.
  • Across five years, Equity Average topped out at $10.4 billion in Q3 2022 and bottomed at $9.6 billion in Q3 2025.
  • The 5-year median for Equity Average is $10.0 billion (2022), against an average of $10.0 billion.
  • The largest annual shift saw Equity Average soared 48.32% in 2021 before it fell 6.85% in 2023.
  • A 5-year view of Equity Average shows it stood at $10.3 billion in 2021, then dropped by 3.36% to $10.0 billion in 2022, then decreased by 1.37% to $9.8 billion in 2023, then grew by 4.74% to $10.3 billion in 2024, then dropped by 6.14% to $9.7 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Equity Average are $9.7 billion (Q4 2025), $9.6 billion (Q3 2025), and $9.6 billion (Q2 2025).